Growing Adoption of Non-Invasive Cancer Diagnostics Propels U.S. Liquid Biopsy Market
According to the latest report by Renub Research, the United States Liquid Biopsy Market is forecasted to reach. The sharp market growth is attributed to increasing demand for non-invasive cancer diagnostics, rising cancer prevalence, technological advancements in genomic sequencing, and growing emphasis on personalized medicine in the U.S. healthcare sector.
Liquid biopsy, a revolutionary diagnostic technique, enables the detection of cancer-related biomarkers such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes from blood and other bodily fluids. Unlike traditional tissue biopsies, liquid biopsies offer real-time monitoring, minimal patient discomfort, and faster turnaround—redefining cancer management in the United States.
👉 Access Full Report on United States Liquid Biopsy Market – Renub Research
Rising Cancer Incidence Fuels Demand for Liquid Biopsy
The increasing burden of cancer across the U.S. is a major driver for the expansion of the liquid biopsy market. According to the American Cancer Society, an estimated 2 million new cancer cases will be diagnosed in 2024, with lung, breast, prostate, and colorectal cancers being the most common.
Liquid biopsy offers an effective tool for early detection, treatment monitoring, and recurrence surveillance. Its ability to detect mutations and alterations at the molecular level allows oncologists to tailor therapies in real time, boosting patient survival rates and reducing healthcare costs.
Advancements in Genomics and Next-Generation Sequencing (NGS)
Technological innovations, especially in next-generation sequencing (NGS) and digital PCR, have significantly enhanced the sensitivity and specificity of liquid biopsy tests. These platforms can detect low levels of ctDNA and offer detailed genomic insights, enabling early-stage cancer detection and monitoring of treatment efficacy.
Companies in the U.S. are rapidly integrating AI-driven analytics, cloud-based platforms, and machine learning algorithms to accelerate interpretation and reporting of complex genetic data. This convergence of diagnostics and digital technologies is pushing liquid biopsy from a research tool to a mainstream clinical solution.
Growth in Companion Diagnostics and Precision Medicine
The United States leads globally in the adoption of companion diagnostics and targeted therapies, making liquid biopsy a crucial component of modern oncology. The ability to track tumor evolution, therapy resistance, and molecular changes without repeated invasive procedures makes liquid biopsy indispensable for precision medicine.
For example, in non-small cell lung cancer (NSCLC), FDA-approved liquid biopsies help detect EGFR, ALK, KRAS, and BRAF mutations, guiding oncologists in choosing appropriate targeted drugs. The increasing development and approval of such companion diagnostics continue to drive clinical adoption across cancer care centers and hospitals.
Strong Regulatory and Reimbursement Support
One of the key enablers of liquid biopsy growth in the U.S. is the supportive regulatory environment. The U.S. Food and Drug Administration (FDA) has approved several liquid biopsy platforms for cancer screening, monitoring, and therapy selection. These include:
- Guardant360 CDx
- FoundationOne Liquid CDx
- Signatera
Additionally, favorable reimbursement policies by Medicare, Medicaid, and private insurers have boosted test accessibility for a wider population. With ongoing efforts from CMS and other agencies to streamline genomic test coverage, more providers and patients are expected to adopt liquid biopsies.
Increasing Applications Beyond Oncology
While oncology remains the primary application area, liquid biopsy is increasingly being explored for non-cancer indications, such as prenatal testing, organ transplant monitoring, and detection of infectious diseases.
Transplant rejection monitoring through cell-free DNA (cfDNA) is gaining traction, offering a non-invasive method to assess donor organ viability and detect rejection episodes earlier than traditional biomarkers.
As research expands and validation continues, the potential of liquid biopsy in broader clinical areas will further strengthen its role in the U.S. diagnostics market.
Market Segmentation – ctDNA Testing Leads the Way
The U.S. liquid biopsy market can be segmented by:
- Biomarkers: ctDNA, CTCs, exosomes, microRNA
- Sample Types: Blood, urine, saliva, cerebrospinal fluid
- Applications: Cancer diagnostics, treatment selection, prognosis, recurrence monitoring, prenatal testing
- End-users: Hospitals, academic research centers, diagnostic laboratories, and oncology clinics
Among biomarkers, ctDNA (circulating tumor DNA) dominates the market due to its wide applicability in tumor detection, mutation profiling, and minimal residual disease (MRD) monitoring. Blood-based biopsies remain the most common sample type owing to ease of collection and consistent reliability.
Key Players and Competitive Landscape
The U.S. liquid biopsy market is highly competitive and innovation-driven, with several biotech companies investing heavily in research, commercialization, and partnerships. Strategic collaborations with pharma companies for co-development of companion diagnostics are also accelerating growth.
Key Companies Profiled in the Report Include:
- Guardant Health, Inc.
- Foundation Medicine, Inc.
- Bio-Rad Laboratories, Inc.
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- Lucence Diagnostics
- Exact Sciences Corporation
- Natera Inc.
- Freenome Holdings, Inc.
- NeoGenomics Laboratories
These companies are expanding their product offerings, investing in CLIA-certified labs, and targeting specific cancer types for maximum clinical impact.
Challenges – Data Interpretation and Standardization
Despite the positive outlook, the liquid biopsy market faces several hurdles:
- Clinical validation and standardization remain challenging, with variability in test sensitivity and specificity across platforms.
- Interpretation of genomic data requires specialized expertise and infrastructure, which can be a barrier for smaller clinics.
- Cost-effectiveness and accessibility in rural and underinsured areas still require policy attention, despite growing coverage.
Addressing these concerns through public-private collaborations, clinician education, and infrastructure development will be key to unlocking the full potential of liquid biopsy.
New Publish Report:
- Europe Cardiac Surgical Devices Market – Innovations & Forecast 2025–2033
- Europe Pepperoni Food Market – Industry Segments & Forecast 2025–2033
- Europe Flavored Milk Market – Product Innovation & Forecast 2025–2033
Future Outlook – Toward Early Cancer Detection and Population Screening
The next frontier for the U.S. liquid biopsy market is multi-cancer early detection (MCED). Companies are investing in pan-cancer tests capable of screening asymptomatic individuals for multiple cancers from a single blood draw. These tests hold the potential to revolutionize population-level screening and reduce cancer mortality through early intervention.
Ongoing clinical trials, such as those led by Grail (Galleri test) and others, indicate strong momentum in this area. As MCED tests receive regulatory clearance and payer acceptance, they will become instrumental in reshaping cancer diagnostics in the U.S.
Renub Research’s latest report provides a deep dive into this high-growth market, with analysis across biomarker types, sample formats, test volumes, major players, and emerging innovations.
About the Company
Renub Research is a Market Research and Consulting Company with more than 15 years of experience, especially in international Business-to-Business Research, Surveys, and Consulting. We provide a wide range of business research solutions that help companies make better business decisions.
We partner with clients across all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele includes key players in Healthcare, Travel & Tourism, Food & Beverages, Power & Energy, Information Technology, Telecom & Internet, Chemicals, Logistics & Automotive, Consumer Goods & Retail, Building & Construction, and Agriculture.
Our core team comprises experienced professionals with graduate, postgraduate, and Ph.D. qualifications in Finance, Marketing, Human Resources, Bio-Technology, Medicine, Information Technology, Environmental Science, and more.
Media Contact
Company Name: Renub Research
Contact Person: Rajat Gupta, Marketing Manager
Phone No: +91-120-421-9822 (IND) | +1-478-202-3244 (USA)
Email: rajat@renub.com
Website: www.renub.com
